Biopharmaceuticals are among the most innovative and sophisticated achievement of science. Biopharmaceuticals are recombinant biological entities obtained from biological sources such as organs and tissues, microorganisms, animal fluids, or genetically modified cells and organisms. With high complexity in the structure and remarkable properties offering high efficacy and few side effects – it forms the core of the pharmaceutical industry. The prevalence of cancer, autoimmune, cardiovascular, and infectious diseases is growing across the globe. Biopharmaceuticals have emerged as an important therapeutic class for the treatment of such diseases and have many advantages over synthetic drugs. These are capable of targeting specific sites and rarely cause side effects that are often observed with synthetic drugs. Biopharmaceuticals offer high specificity and activity. They have enabled the treatment of patients who do not respond/poorly respond to the traditional synthetic drugs. Owing to these reasons, the biopharmaceuticals are expected to witness the surge in the demand over next few years.
As the demand for biopharmaceutical rises, the equipment and consumables used in their production are likely to witness high growth. At present, many of the large-scale bioproduction plants are based on stainless-steel equipment. However, the trend is shifting and plastic/polymer-based single-use technology is rapidly replacing the traditional equipment used in bioproduction. In fact, single-use technology has exhibited more than 85% penetration in the research bioproduction and is also witnessing growing adoption in commercial bioproduction. The use of disposables eliminates the need for complicated and expensive cleaning and sterilization process of equipment. It also reduces the capital cost, equipment installation costs, and validation costs. Moreover, single-use bioprocessing systems increase the productivity of the process by offering low-level product contamination, operational flexibility, low labor cost, faster batch turn-around, and product changeover compared to conventional stainless-steel facilities. In addition, simplification of processes through single-use technology and elimination of cleaning steps and associated documentation greatly reduces the regulatory risks. Owing to these reasons, the key players operating in the bioprocessing equipment and consumables market are strategically focusing on enriching their product basket with single-use platforms.
Hence, increasing penetration of single-use technology in bioproduction is expected to propel the biopharmaceutical equipment and consumables market growth with a lucrative CAGR of 14.8% to reach USD 22,340.0 million by 2023, according to the Meticulous Research®.